Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combination Products: US FDA Extends Safety-Reporting Deadline

Executive Summary

After major post-market safety reporting rule in 2016, guidance adds context for companies developing combination products. FDA also extends compliance deadlines in many cases until 2019.

You may also be interested in...



Combo-Product Sponsors Gain Some Favored Changes In Final Post-Market Reporting Rule

US FDA’s final rule includes several clarifications about its scope and definitions, and includes some additional reporting requirements.

Combo Product Sponsors Convince US FDA To Change Postmarket Reporting Rule

Final reg includes several clarifications about its scope and definitions, and also includes some additional reporting requirements.

Massive Family Dollar Rat Infestation Leads To Multi-State Recall

The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel